Preparation of budesonide nanosuspensions for pulmonary delivery: Characterization, in vitro release and in vivo lung distribution studies

被引:19
作者
Zhang, Yuan [1 ]
Zhang, Jianhua [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Pediat, Shanghai 200233, Peoples R China
关键词
budesonide; characteristic; in vitro; in vivo; nanosuspension; ASTHMA CONTROL; GUIDELINES; CRYSTALLIZATION; COMBINATION; EOSINOPHILS; OPTIONS;
D O I
10.3109/21691401.2014.944645
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The main objective of the present article was to prepare stable and well-dispersible budesonide (BUD) nanosuspensions by microfluidizer method. The morphology, particle size, and zeta potential of formulation were investigated and in vitro release and in vivo lung distribution were evaluated. Characterizations showed that BUD nanosuspensions were spherical in shape with a smooth surface. The measured average particle size was 122.5 +/- 6.3 nm, and potential was - 13.6 +/- 0.4 mV. In vitro release behavior of three batches BUD nanosuspensions had a good reproduction. The deposition distribution of BUD different formulations was measured using a modified multi-stage liquid collision method. The data showed that BUD nanosuspensions have the most outstanding deposition distribution with fine particle ratio 82.2%. Compared with normal particle and micronized particles, nanosuspensions were easier to be distributed in lung. After inhalation of 1 h, the drug concentration can reach 872.9 ng/g, which was extremely significantly different from normal particles (p < 0.01) and significantly different from micronized particles (p < 0.05).
引用
收藏
页码:285 / 289
页数:5
相关论文
共 18 条
  • [1] Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control
    Barnes, Peter J.
    [J]. BRITISH MEDICAL JOURNAL, 2007, 335 (7618): : 513 - 513
  • [2] Brightling CE, 2013, AM J RESP CRIT CARE, V188, P1468, DOI 10.1164/rccm.201305-0996LE
  • [3] New therapeutic options for allergic rhinitis: Back to the future with intranasal corticosteroid aerosols
    Carr, Warner W.
    [J]. AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2013, 27 (04) : 309 - 313
  • [4] Nanosuspensions in Drug Delivery: Recent Advances, Patent Scenarios, and Commercialization Aspects
    Chavhan, Sandip S.
    Petkar, Kailash C.
    Sawant, Krutika K.
    [J]. CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2011, 28 (05): : 447 - 488
  • [5] Prediction of In Vivo Atenolol Removal by High-Permeability Hemodialysis Based on an In Vitro Model
    Daheb, Kahina
    Lecours, Jean-Philippe
    Lipman, Mark L.
    Hildgen, Patrice
    Roy, Julie J.
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2013, 16 (05): : 657 - 664
  • [6] Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: A systematic review
    Dyer M.J.
    Halpin D.M.G.
    Stein K.
    [J]. BMC Family Practice, 7 (1)
  • [7] ANALYSIS OF DATA ON MEDICAMENT RELEASE FROM OINTMENTS
    HIGUCHI, WI
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1962, 51 (08) : 802 - &
  • [8] Crystalline Nanosuspensions as Potential Toxicology and Clinical Oral Formulations for BCS II/IV Compounds
    Kesisoglou, Filippos
    Mitra, Amitava
    [J]. AAPS JOURNAL, 2012, 14 (04): : 677 - 687
  • [9] Global Initiative for Asthma (GINA) guidelines: 15 years of application
    Kroegel, Claus
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (03) : 239 - 249
  • [10] A mini review of nanosuspensions development
    Liu, Yue
    Xie, Pengcheng
    Zhang, Dianrui
    Zhang, Qiang
    [J]. JOURNAL OF DRUG TARGETING, 2012, 20 (03) : 209 - 223